-
HST 001 – we completed our strategic evaluation of the HST 001 program taking into consideration the results from our Phase 1b/2a clinical trial of HST 001 as announced earlier this year, and as a result, we will suspend development of this program. While HST 001 has demonstrated a favorable safety and tolerability profile in androgenic alopecia in men, the development resources required to potentially achieve an acceptable efficacy threshold are substantial in terms of cost and time. Therefore, we believe the best business decision at this time, is to redirect these resources towards our high value orthopedic programs.
hairlosscure2020的博主在得知这一消息后写道:
Well, Histogen was likely the biggest joke in the history of anticipated hair loss treatments. Worse than Aderans and Intercytex. Worse than Aclaris. They fooled us twice over the course of 14 years since inception. Now, per today’s news, we know that HST-001 is over once and for all.
好吧,Histogen是脱发治疗科技史上最大的笑话。比Aderans公司,Intercytex公司以及Aclaris公司都更糟糕。14年间,欺骗过我们两次。可是,根据今天的新闻,HST-001永远的结束了!
今天我们依旧在寻找各种生长因子,类似的欺骗与失望依旧在上演,重复昨天的故事。但我依然要说:再见,Histogen!再见,稚嫩的青春!
原文地址:点击此处查看原文
纳闻 | 真实新闻时事动态:再见,Histogen!